GRAP2 RNAi Summary
Specificity |
Homo sapiens GRB2-related adaptor protein 2 (GRAP2), mRNA
|
Gene |
GRAP2
|
Applications/Dilutions
Application Notes |
This RNAi causes protein knockdown.
|
Packaging, Storage & Formulations
Storage |
Store at -20C. Avoid freeze-thaw cycles.
|
Notes
This product is produced by and distributed for Abnova, a company based in Taiwan.
Alternate Names for GRAP2 RNAi
- Adapter protein GRID
- GADS
- GADSSH3-SH2-SH3 adapter Mona
- GRAP2
- GRB2L
- GRB-2-like protein
- GRB2-related adapter protein 2
- GRB2-related adaptor protein 2
- GRB2-related protein with insert domain
- GRBLG
- GRBLGGRAP-2
- GRBX
- Grf40 adapter protein
- Grf40
- grf-40
- GRID
- GRIDGRPL
- Growth factor receptor-binding protein
- growth factor receptor-bound protein 2-related adaptor protein 2
- GRPL
- Hematopoietic cell-associated adapter protein GrpL
- hematopoietic cell-associated adaptor protein GRPL
- Mona
- P38
- Protein GADS
- SH3-SH2-SH3 adaptor molecule
Background
Position of the Chimera RNAi. The related RNAi products listed were designed from different accesion number but sharing the same RNAi sequence. Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene.聽 The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo.聽 Chimera RNAi has many advantages over the conventional siRNAs.聽 First, it has been demonstrated to have reliable knock-down for over 10,000 human genes.聽 Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence.聽 Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected.聽 Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.